Clinical Trial Update: Renohemodynamic Effects of Combined empagliflOzin and LosARtan [Phase 4]

View source ↗

Summary

Phase 4 trial updating Reno hemodynamic effects of combined empagliflozin and losartan in type 2 diabetes and diabetic kidney disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Kidney Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)
• Losartan (losartan)

Snippet

Sponsor: Amsterdam UMC, location VUmc | Conditions: Diabetes Mellitus, Type 2, Diabetic Kidney Disease | Phase 4 | Status: COMPLETED